FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096804956> ?p ?o ?g. }

• W2096804956 endingPage "8" @default.
• W2096804956 startingPage "7" @default.
• W2096804956 abstract "Based on pre-clinical data showing patterns of aberrant methylation in myelodysplastic syndromes (MDS) and evidence of cellular differentiation associated with reversal of methylation by decitabine [1–3], MDS became a prime candidate for development of the hypomethylating agents decitabine and 5-azacytidine. Noteworthy, albeit fewer, reports have been published which suggest that acute lymphoblastic leukemia (ALL) might also be amenable to intervention with these agents. Some of these reports provide evidence that promoter regions of genes associated with biological and prognostic importance in ALL are methylated and can be demethylated with exposure to decitabine, including the putative tumor suppressor gene FHIT in pediatric ALL [4,5], and ERG isoforms and BMP-6 in T-ALL [6,7]. Arraybased approaches have also identified a multitude of additional aberrantly methylated genes in ALL that may warrant further investigation [8,9]. There are few reports of clinical investigations exploring the activity of decitabine or 5-azacytidine monotherapy in ALL. The authors of a Letter to the Editor in this issue of Leukemia and Lymphoma cite the report of a single pediatric patient with ALL who achieved a complete response (CR) with decitabine and dexamethasone, and an older study wherein two responses were seen among 23 patients with ALL receiving three different schedules of 5-azacytidine. Additional patients with ALL may be included in acute leukemia studies, such as the one patient who was treated in a phase 1 decitabine study, but was not listed among the responders [10], but response data are not yet available for a uniformly treated cohort with ALL. More recently, interim data from a phase 1 study of decitabine in relapsed and refractory ALL was reported in abstract form in 2009 [11], and updated results should be forthcoming. In this Letter to the Editor, the authors describe the clinical course of a single adult patient with concurrent MDS and ALL who achieved a morphologic remission of ALL with MDS-directed 5-azacytidine therapy [12]. Post-treatment, the patient had cytogenetic evidence of persistent MDS with residual cytopenias, presumably due to MDS. This observation, in addition to available pre-clinical data and earlier clinical reports, provides a hint that the epigenetic regulation of genes contributing to the pathophysiology of ALL should be further and more systematically studied, and that consideration be given to continued testing of DNA methyltransferase inhibitors in pediatric and adult patients with ALL in the context of clinical trials. For example, future trials could target untreated older patients with ALL, given their characteristic relative intolerance to standard therapeutic approaches and the acceptable toxicity of these agents in MDS trials in which the median age was approximately 70 years. Younger patients would also benefit from more treatment options. In the arena of new drug development for acute leukemias, ALL often ‘takes a back seat’ to acute myeloid leukemia. Although hypomethylating agents have secured their place in the management of acute myeloid leukemia and MDS, this report and others suggest that the potential of the hypomethylating agents in ALL and other lymphoid malignancies may be untapped." @default.
• W2096804956 created "2016-06-24" @default.
• W2096804956 creator A5001124933 @default.
• W2096804956 creator A5045087884 @default.
• W2096804956 date "2010-10-07" @default.
• W2096804956 modified "2023-09-26" @default.
• W2096804956 title "Hypomethylating agents in acute lymphoblastic leukemia: untapped potential?" @default.
• W2096804956 cites W1985964461 @default.
• W2096804956 cites W2020269967 @default.
• W2096804956 cites W2026123032 @default.
• W2096804956 cites W2032004540 @default.
• W2096804956 cites W2066183133 @default.
• W2096804956 cites W2074641381 @default.
• W2096804956 cites W2082440228 @default.
• W2096804956 cites W2109811271 @default.
• W2096804956 cites W2109895173 @default.
• W2096804956 cites W2145750252 @default.
• W2096804956 cites W90521908 @default.
• W2096804956 doi "https://doi.org/10.3109/10428194.2010.524330" @default.
• W2096804956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20929335" @default.
• W2096804956 hasPublicationYear "2010" @default.
• W2096804956 type Work @default.
• W2096804956 sameAs 2096804956 @default.
• W2096804956 citedByCount "1" @default.
• W2096804956 countsByYear W20968049562014 @default.
• W2096804956 crossrefType "journal-article" @default.
• W2096804956 hasAuthorship W2096804956A5001124933 @default.
• W2096804956 hasAuthorship W2096804956A5045087884 @default.
• W2096804956 hasConcept C104317684 @default.
• W2096804956 hasConcept C150194340 @default.
• W2096804956 hasConcept C190727270 @default.
• W2096804956 hasConcept C203014093 @default.
• W2096804956 hasConcept C2776012956 @default.
• W2096804956 hasConcept C2776863199 @default.
• W2096804956 hasConcept C2778461978 @default.
• W2096804956 hasConcept C2909962599 @default.
• W2096804956 hasConcept C502942594 @default.
• W2096804956 hasConcept C54355233 @default.
• W2096804956 hasConcept C71924100 @default.
• W2096804956 hasConcept C86803240 @default.
• W2096804956 hasConceptScore W2096804956C104317684 @default.
• W2096804956 hasConceptScore W2096804956C150194340 @default.
• W2096804956 hasConceptScore W2096804956C190727270 @default.
• W2096804956 hasConceptScore W2096804956C203014093 @default.
• W2096804956 hasConceptScore W2096804956C2776012956 @default.
• W2096804956 hasConceptScore W2096804956C2776863199 @default.
• W2096804956 hasConceptScore W2096804956C2778461978 @default.
• W2096804956 hasConceptScore W2096804956C2909962599 @default.
• W2096804956 hasConceptScore W2096804956C502942594 @default.
• W2096804956 hasConceptScore W2096804956C54355233 @default.
• W2096804956 hasConceptScore W2096804956C71924100 @default.
• W2096804956 hasConceptScore W2096804956C86803240 @default.
• W2096804956 hasIssue "1" @default.
• W2096804956 hasLocation W20968049561 @default.
• W2096804956 hasLocation W20968049562 @default.
• W2096804956 hasOpenAccess W2096804956 @default.
• W2096804956 hasPrimaryLocation W20968049561 @default.
• W2096804956 hasRelatedWork W2361810291 @default.
• W2096804956 hasRelatedWork W2364468205 @default.
• W2096804956 hasRelatedWork W2398513204 @default.
• W2096804956 hasRelatedWork W2419219125 @default.
• W2096804956 hasRelatedWork W2428449797 @default.
• W2096804956 hasRelatedWork W2923049128 @default.
• W2096804956 hasRelatedWork W3030982478 @default.
• W2096804956 hasRelatedWork W4206167433 @default.
• W2096804956 hasRelatedWork W62609383 @default.
• W2096804956 hasRelatedWork W96278395 @default.
• W2096804956 hasVolume "52" @default.
• W2096804956 isParatext "false" @default.
• W2096804956 isRetracted "false" @default.
• W2096804956 magId "2096804956" @default.
• W2096804956 workType "article" @default.